![]() |
市場調査レポート
商品コード
232818
非アルコール性脂肪性肝炎:パイプライン分析Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020 |
非アルコール性脂肪性肝炎:パイプライン分析 |
出版日: 2020年07月31日
発行: Global Markets Direct
ページ情報: 英文 1101 Pages
納期: 即納可能
![]() |
非アルコール性脂肪性肝炎(NASH)とは、肝臓に蓄積された脂肪肝により引き起こされる炎症です。肝臓の瘢痕化を発生・悪化させ、それがさらに硬変の原因ともなっています。主な症状には、倦怠感や原因不明の体重減少、全身の衰弱、腹部右側の腹痛などがあります。疾病素質として、肥満や2型糖尿病、高コレステロール、高中性脂肪(トリグリセリド)、メタボリック症候群などがあります。
当レポートでは、世界各国での非アルコール性脂肪性肝炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2020, provides an overview of the Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline landscape.
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 62, 51, 1, 8, 175, 70 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.
Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.